Johnson & Johnson

- Johnson & Johnson recently executed the Kenvue separation, generating significant cash and value via debt offering and IPO. - Post-separation, J&J reduced its outstanding share count by approximately 191 million shares (~7%) and retained about 180 million Kenvue stock shares. - The company maintains a strong credit profile with a net debt position of $6 billion and cash and marketable securities of approximately $24 billion. - Free cash flow year-to-date through Q3 2023 was ~$12 billion, supporting capital allocation priorities. - J&J plans to continue executing disciplined capital allocation via business development, dividend increases, and share repurchases. - No explicit mention of plans for new fundraising through fresh debt or equity issuance was stated. - The company focuses on funding organic growth, pipeline investments, and potential strategic business development initiatives with existing resources and financial strength.

- Johnson & Johnson is progressively adding manufacturing capacity for Carvykti, including: - Increasing capacity at the launch site in New Jersey. - Rolling out a manufacturing site in Belgium, Europe. - Utilizing excess capacity from Novartis. - Expanding lentivirus component production at their factory in Switzerland. - Building a new factory in the Netherlands to be operational next year to support lentivirus production. - MedTech segment is implementing a restructuring program to simplify and focus operations over a three-year period, expected to complete by end of 2025, including: - Exiting selected markets and product lines. - Anticipating modest revenue deduction (~$250 million over two years) in Orthopedics but with expectations to improve margins and profitability. - Multiple new clinical development programs are planned, including: - Anthem trial for J&J-2113 beginning this month. - Phase 3 ICONIC trial in moderate to severe plaque psoriasis expected to start in November. - No explicit mention of other large-scale capital expenditure, emphasizing disciplined business development aligned with strategic and financial parameters.

- MedTech segment expects continued procedural growth of 5% to 7% in 2024, maintaining elevated levels seen in 2023. - Bariatric business sees potential short-term impact from GLP-1 treatments but expects complementary growth with increased obesity awareness. - Immunology business, led by Tremfya, projects significant growth with upcoming approvals in ulcerative colitis and Crohn's disease; Tremfya showed 25.1% growth recently. - Oncology growth is strong, with products like Carvykti showing high demand and expanding treatment lines. - Innovative Medicines group confident in achieving $57 billion revenue target by 2025, driven by key assets and pipeline progress. - China remains a key growth driver despite headwinds from value-based procurement (VBP). - Overall, top-line growth is expected to remain healthy into 2024 with continued expansion driven by new product launches and market expansion.

- For 2023, Johnson & Johnson raised guidance with expected operational sales growth of 8.5% to 9%, adjusted pre-tax operating margin improvement of ~50 basis points, and adjusted earnings per share (EPS) growth of approximately 12.5% at midpoint. - Full-year 2023 adjusted EPS guidance is $10.02 to $10.08, up by $0.10 at midpoint. - The share count reduction from Kenvue separation will fully impact 2024 financials, positively affecting EPS. - For 2024, top-line growth is expected to remain healthy, with sales and procedural volumes roughly flat to slightly improved in MedTech. - Margin guidance for 2024 is not provided yet, but continuing similar margins to 2023 is anticipated. - Growth in Innovative Medicines driven by key brands, new product launches, and a strong pipeline with multiple data readouts and approvals planned. - Biosimilar entry for Stelara in the US is not expected until 2025, supporting near-term pharma revenues. - Currency headwinds expected in both 2023 and 2024 may negatively impact reported earnings.

The transcript from pages 3, 4, 5, and 6 of the document does not provide specific information about current or expected orderbook or pending orders for Johnson & Johnson. Instead, it focuses on topics such as: - Immunology portfolio growth and outlook. - Progress and excitement around the Ottava surgical robotics platform. - Product launches and pipeline updates including CARVYTI, TECVAYLI, and MARIPOSA. - Market dynamics including the impact of biosimilars, pricing, and procedural growth. - Manufacturing scale-ups, particularly for CARVYTI. - Litigation updates related to talc cases. - Margin and growth expectations for 2023 and 2024. No explicit statements were made regarding orderbook size, value, or pending orders.